Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Incyte Corporation

Market Cap 19.78B 17.19B 15.82B 14.87B 27.88B 1,869B 28.19B 188B 72.92B 918B 74.22B 72.63B 3,176B P/E 2026 *
15x
P/E 2027 * 12.7x
Enterprise Value 14.79B 12.86B 11.83B 11.13B 20.86B 1,398B 21.09B 140B 54.55B 687B 55.52B 54.33B 2,376B EV / Sales 2026 *
2.63x
EV / Sales 2027 * 2.06x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day-0.76%
1 week-4.11%
Current month+2.33%
1 month+3.86%
3 months+6.44%
6 months+2.02%
Current year+0.22%
1 week 98.25
Extreme 98.25
109.69
1 month 92.18
Extreme 92.18
110.34
Current year 89.25
Extreme 89.25
112.29
1 year 66.74
Extreme 66.7401
112.29
3 years 50.27
Extreme 50.27
112.29
5 years 50.27
Extreme 50.27
112.29
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
06-08Free

Director

7,753 0.0039%
06-08Free

Director

7,753 0.0039%
06-08
FBS Associates LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-0.76%-4.11%+38.99%+56.56% 19.93B
-1.11%-1.34%+16.31%-22.36% 62.54B
+0.96%-3.77%+55.85%+194.24% 55.22B
+2.78%+37.00%+37.00%+37.00% 40.9B
+0.51%+7.36%-55.34%-61.57% 35.99B
+1.56%-0.22%+51.61%-33.22% 28.88B
+11.55%+29.48%+137.69%-51.99% 21.98B
-2.03%+2.32%-6.79%+103.95% 16.95B
+2.32%+1.06%+52.60%+95.04% 15.87B
+1.13%-0.43%+63.81%+348.97% 13.05B
Average +0.56%+2.10%+39.17%+66.66% 31.13B
Weighted average by Cap. +0.54%+1.64%+33.64%+49.71%

Financials

2026 *2027 *
Net sales 5.64B 4.9B 4.51B 4.24B 7.94B 533B 8.03B 53.52B 20.78B 262B 21.15B 20.7B 905B 6.3B 5.47B 5.04B 4.74B 8.88B 595B 8.98B 59.8B 23.22B 292B 23.63B 23.13B 1,011B
Net income 1.37B 1.19B 1.1B 1.03B 1.94B 130B 1.96B 13.04B 5.06B 63.74B 5.15B 5.04B 220B 1.64B 1.42B 1.31B 1.23B 2.31B 155B 2.34B 15.56B 6.04B 76.09B 6.15B 6.02B 263B
Net Debt -4.98B -4.33B -3.98B -3.75B -7.02B -471B -7.1B -47.31B -18.37B -231B -18.7B -18.3B -800B -6.83B -5.94B -5.46B -5.14B -9.63B -646B -9.74B -64.86B -25.18B -317B -25.63B -25.08B -1,097B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
17/06/26 98.99 $ -0.76% 1,683,161
16/06/26 99.75 $ -2.19% 1,556,318
15/06/26 101.98 $ -6.04% 2,815,109
12/06/26 108.53 $ +0.65% 1,488,907
11/06/26 107.83 $ +2.32% 2,318,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
98.99USD
Average target price
109.35USD
Spread / Average Target
+10.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!